Gosuranemab Fails to Show Efficacy in Phase 2 Progressive Supranuclear Palsy Trial
Gosuranemab failed to meet its primary and key secondary goals in a Phase 2 study evaluating its use in treating progressive supranuclear palsy, an atypical parkinsonian disorder, its developer, Biogen, has announced. Based on these results, Biogen will cease the clinical development of gosuranemab for this and other neurodegenerative diseases…